San Mateo, CA-based Epocrates has great momentum. Back in April of 2008 this clinical data provider filed for an estimated $75 million initial public offering, but it appears to have been pulled or stalled. The firm's investors include Sprout Group, Interwest Partners, Three Arch Partners, Draper Fisher Jurvetson, Bay City Capital and Goldman Sachs.
Founded in 1998, the 200-employee firm develops clinical information and decision support tools that enable healthcare professionals to find answers more quickly and confidently at the point of care.
More than 600,000 healthcare professionals, including one in four U.S. physicians, use Epocrates’ mobile and web-based products to help them reduce medical errors, improve patient care and increase productivity.
Epocrates' new version of their Essentials suite was developed exclusively for the iPhone platform. It takes advantage of the iPhone's touch-screen interface, and introduces new disease content, features and functionality to the platform. The Essentials premium software solution includes:
* Drug prescribing and safety information for more than 3,300 drugs, including pill pictures
* Peer-reviewed disease content and evidence-based differential diagnosis developed in conjunction with the BMJ Group, publisher of the British Medical Journal
* Infectious disease treatment guide with empiric and specific treatment recommendations
* Hundreds of diagnostic and laboratory tests for interpretation and diagnostic support
* 600+ alternative (herbal) medications with drug interactions
* MedMath medical calculators including commonly-used pregnancy wheel and unit conversions.
Epocrates offerings are about convenient access to the critical information doctors need all on one device right at the point of care. The firm's suite features cross-linking between the drug, disease and diagnostic content and can be used to support a patient’s consultation from diagnosis to treatment.
NOTE: Add us on twitter-- we're www.twitter.com/marketintellnow
